Publication
Resection of Colorectal Liver Metastases After Second-Line Chemotherapy: Is It Worthwhile? A LiverMetSurvey Analysis of 6415 Patients
dc.contributor.author | Adam, R | |
dc.contributor.author | Yi, B | |
dc.contributor.author | Innominato, PF | |
dc.contributor.author | Barroso, E | |
dc.contributor.author | Laurent, C | |
dc.contributor.author | Giuliante, F | |
dc.contributor.author | Capussotti, L | |
dc.contributor.author | Lapointe, R | |
dc.contributor.author | Regimbeau, JM | |
dc.contributor.author | Lopez-Ben, S | |
dc.contributor.author | Isoniemi, H | |
dc.contributor.author | Hubert, C | |
dc.contributor.author | Lin, JK | |
dc.contributor.author | Gruenberger, T | |
dc.contributor.author | Elias, D | |
dc.contributor.author | Skipenko, OG | |
dc.contributor.author | Guglielmi, A | |
dc.date.accessioned | 2018-03-02T15:20:23Z | |
dc.date.available | 2018-03-02T15:20:23Z | |
dc.date.issued | 2017 | |
dc.description.abstract | PURPOSE: Patient outcome after resection of colorectal liver metastases (CLM) following second-line preoperative chemotherapy (PCT) performed for insufficient response or toxicity of the first-line, is little known and has here been compared to the outcome following first-line. PATIENTS AND METHODS: From January 2005 to June 2013, 5624 and 791 consecutive patients of a prospective international cohort received 1 and 2 PCT lines before CLM resection (group 1 and 2, respectively). Survival and prognostic factors were analysed. RESULTS: After a mean follow-up of 30.1 months, there was no difference in survival from CLM diagnosis (median, 3-, and 5-year overall survival [OS]: 58.6 months, 76% and 49% in group 2 versus 58.9 months, 71% and 49% in group 1, respectively, P = 0.32). After hepatectomy, disease-free survival (DFS) was however shorter in group 2: 17.2 months, 27% and 15% versus 19.4 months, 32% and 23%, respectively (P = 0.001). Among the initially unresectable patients of group 1 and 2, no statistical difference in OS or DFS was observed. Independent predictors of worse OS in group 2 were positive primary lymph nodes, extrahepatic disease, tumour progression on second line, R2 resection and number of hepatectomies/year <50. Positive primary nodes, synchronous and bilateral metastases were predictors of shorter DFS. Initial unresectability did not impact OS or DFS in group 2. CONCLUSION: CLM resection following second-line PCT, after oncosurgically favourable selection, could bring similar OS compared to what observed after first-line. For initially unresectable patients, OS or DFS is comparable between first- and second-line PCT. Surgery should not be denied after the failure of first-line chemotherapy. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Eur J Cancer. 2017 Jun;78:7-15 | pt_PT |
dc.identifier.doi | 10.1016/j.ejca.2017.03.009 | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.17/2922 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Elsevier | pt_PT |
dc.subject | Antibodies, Monoclonal | pt_PT |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | pt_PT |
dc.subject | Camptothecin | pt_PT |
dc.subject | Catheter Ablation | pt_PT |
dc.subject | Cetuximab | pt_PT |
dc.subject | Disease Progression | pt_PT |
dc.subject | Disease-Free Survival | pt_PT |
dc.subject | Female | pt_PT |
dc.subject | Hepatectomy | pt_PT |
dc.subject | Humans | pt_PT |
dc.subject | Liver Neoplasms | pt_PT |
dc.subject | Lymphatic Metastasis | pt_PT |
dc.subject | Male | pt_PT |
dc.subject | Middle Aged | pt_PT |
dc.subject | Postoperative Care | pt_PT |
dc.subject | Preoperative Care | pt_PT |
dc.subject | Prospective Studies | pt_PT |
dc.subject | Registries | pt_PT |
dc.subject | Colonic Neoplasms | pt_PT |
dc.subject | Rectal Neoplasms | pt_PT |
dc.subject | CHLC CHBPT | pt_PT |
dc.title | Resection of Colorectal Liver Metastases After Second-Line Chemotherapy: Is It Worthwhile? A LiverMetSurvey Analysis of 6415 Patients | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.endPage | 15 | pt_PT |
oaire.citation.startPage | 7 | pt_PT |
oaire.citation.title | European Journal of Cancer | pt_PT |
oaire.citation.volume | 78 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |